Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

684
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
684
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

759
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
759
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.

Advances in therapy·2026
Same author

Structure-Function Decoupling of the Sensorimotor and Default Mode Networks in Black Americans With MS.

Annals of clinical and translational neurology·2026
Same author

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Black and Non-Hispanic White persons with multiple sclerosis: Social determinants of health and health inequities.

Multiple sclerosis and related disorders·2025
Same author

Emerging Subspecialties in Neurology: Cortical Career as Neurology Program Director.

Neurology·2025

Related Experiment Video

Updated: Apr 3, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.5K

Novel Agents for Relapsing Forms of Multiple Sclerosis.

Rebecca Straus Farber1, Asaff Harel1, Fred Lublin1

  • 1Icahn School of Medicine at Mount Sinai, New York, NY 10029; email: rebecca.straus-farber@mssm.edu , asaff.harel@mountsinai.org , fred.lublin@mssm.edu.

Annual Review of Medicine
|September 23, 2015
PubMed
Summary

Five new multiple sclerosis (MS) drugs approved since 2004 offer improved treatment options but require careful physician monitoring for new safety concerns. This review details approved and emerging therapies for relapsing MS.

Keywords:
alemtuzumabdaclizumabdimethyl fumaratefingolimodmultiple sclerosisnatalizumabocrelizumabofatumumabteriflunomide

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K

Related Experiment Videos

Last Updated: Apr 3, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.5K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

28.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Immunology

Background:

  • Multiple sclerosis (MS) treatment has evolved significantly since 2004.
  • Five novel disease-modifying therapies for relapsing MS have been FDA-approved.
  • These new agents offer enhanced efficacy and tolerability but introduce unique safety considerations.

Purpose of the Study:

  • To review recently approved multiple sclerosis therapies.
  • To examine the mechanism of action, clinical data, and safety profiles of new MS drugs.
  • To discuss emerging treatments in late-stage clinical trials for multiple sclerosis.

Main Methods:

  • Review of FDA-approved drugs for relapsing multiple sclerosis since 2004.
  • Analysis of clinical trial data, safety, and monitoring requirements for natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtuzumab.
  • Evaluation of promising agents in late-phase trials, including daclizumab, ocrelizumab, and ofatumumab.

Main Results:

  • Detailed review of five approved MS medications: natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtuzumab.
  • Discussion of their distinct mechanisms of action, efficacy in clinical trials, and associated safety profiles.
  • Overview of ongoing research and data for investigational MS therapies.

Conclusions:

  • The expanding therapeutic landscape for multiple sclerosis necessitates a thorough understanding of new drug profiles.
  • Physicians must be aware of the specific safety concerns and monitoring needs for each new agent.
  • Ongoing research promises further advancements in managing relapsing forms of MS.